Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment

Plain-language summary

This study evaluates a longitudinal cancer genetics follow-up program for patients carrying a hereditary cancer syndrome (HCS) in a rural setting. Adults aged 18 and over who were found more than a year ago to carry a pathogenic germline variant in a cancer-risk gene can take part. It is a study without an assigned phase and is enrolling by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Enrolling by invitation

Sponsor

University of Vermont Medical Center

Intervention

Longitudinal Cancer Genetics Follow-Up Program

Start date

12/29/2023

Estimated completion

12/1/2027

Countries

United States

Related genes

Locations

• Burlington, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients of all genders must be ≥ 18 years of age.
* Patients must have a known pathogenic germline variant in a cancer risk gene that was identified by a CLIA-approved lab more than one year ago.
* Patients must be able to accurately provide self-report data (i.e., per clinical judgment, cognitive function is intact).
* Patients must be able to complete questionnaires in English.
* Patients must have the ability to provide informed consent.

Exclusion Criteria:

\- Patients who tested positive for a germline pathogenic variant associated with cancer risk \< 1 year ago are not eligible.